α7-Nicotinic receptor antagonists at the beginning of a clinical era for NSCLC and Mesothelioma? (original) (raw)

SSR180711, a Novel Selective α7 Nicotinic Receptor Partial Agonist: (1) Binding and Functional Profile

Neuropsychopharmacology, 2007

Hypolipidemic effect of a pro-drug containing nicotinic acid in rats

Central European Journal of Medicine, 2006

Native Nicotinic Acetylcholine Receptors in Human Imr32 Neuroblastoma Cells: Functional, Immunological and Pharmacological Properties

Claudia Verderio

European Journal of Neuroscience, 1995

View PDFchevron_right

Nicotinic antagonist effects on functional attention networks

Tilo Kircher

International Journal of Neuropsychopharmacology, 2009

View PDFchevron_right

Choline and nicotine increase glioblastoma cell proliferation by binding and activating α7- and α9- containing nicotinic receptors

Antonio Daga

Pharmacological Research, 2021

View PDFchevron_right

SSR591813, a Novel Selective and Partial α4β2 Nicotinic Receptor Agonist with Potential as an Aid to Smoking Cessation

Frédéric Galli

Journal of Pharmacology and Experimental Therapeutics, 2003

View PDFchevron_right

Feasibility and effectiveness of inhaled carboplatin in NSCLC patients

George Zachariadis

Investigational New Drugs, 2011

View PDFchevron_right

Neuronal Nicotinic Receptors as Brain Targets for Pharmacotherapy of Drug Addiction

Shafiqur Rahman

CNS & Neurological Disorders - Drug Targets, 2008

View PDFchevron_right

Inhibition of non-neuronal α7-nicotinic receptor reduces tumorigenicity in A549 NSCLC xenografts

Michele Cilli

International Journal of Cancer, 2009

View PDFchevron_right

α7 nicotinic acetylcholine receptor upregulation by anti-apoptotic Bcl-2 proteins

David Bredt

Nature Communications, 2019

View PDFchevron_right

αC-Conotoxin PrXA: A New Family of Nicotinic Acetylcholine Receptor Antagonists

Elsie Alin Sánchez Jiménez 102

Biochemistry, 2007

View PDFchevron_right

Nicotinic acetylcholine receptors: upregulation, age-related effects and associations with drug use

Jerry Stitzel

Genes, Brain and Behavior, 2015

View PDFchevron_right

Application of nicotine enantiomers, derivatives and analogues in therapy of neurodegenerative disorders

Dariusz Pogocki

European Journal of Pharmacology, 2007

View PDFchevron_right

Nicotinic acetylcholine receptor variation and response to smoking cessation therapies

Rachel Tyndale

Pharmacogenetics and Genomics, 2013

View PDFchevron_right

Trapping of Nicotinic Acetylcholine Receptor Ligands Assayed byIn VitroCellular Studies andIn VivoPET Imaging

William Green

The Journal of Neuroscience, 2022

View PDFchevron_right

Nicotine promotes arteriogenesis

Christopher Heeschen

Journal of the American College of Cardiology, 2003

View PDFchevron_right

Inhibition of Nonneuronal α7-Nicotinic Receptor for Lung Cancer Treatment

Laura Paleari

American Journal of Respiratory and Critical Care Medicine, 2009

View PDFchevron_right

Recent progress in cancer therapeutics

Michael Rossbach

Translational oncology, 2009

View PDFchevron_right

Maraula et al. Neuropharmacol. 2012

Felicita Pedata

View PDFchevron_right

Modeling nicotinic neuromodulation from global functional and network levels to nAChR based mechanisms

Boris Gutkin

Acta Pharmacologica Sinica, 2009

View PDFchevron_right

Natural agents targeting the α7-nicotinic-receptor in NSCLC: A promising prospective in anti-cancer drug development

patrizia russo

International Journal of Cancer, 2008

View PDFchevron_right

Functional Properties of Homomeric, Human alpha7-Nicotinic Acetylcholine Receptors Heterologously Expressed in the SH-EP1 Human Epithelial Cell Line

Yen-Ping Kuo

Journal of Pharmacology and Experimental Therapeutics, 2003

View PDFchevron_right

[¹⁸F]Nifene test-retest reproducibility in first-in-human imaging of α4β2* nicotinic acetylcholine receptors

Bradley Christian

Synapse, 2017

View PDFchevron_right

New mechanism-based anticancer drugs that act as orphan nuclear receptor agonists

Sudhakar Reddy Chintharlapalli

View PDFchevron_right

Clin-Neuro/Medical Oncology

C. Dealis

Neuro-Oncology, 2012

View PDFchevron_right

α7-Nicotinic receptor antagonists at the beginning of a clinical era for NSCLC and Mesothelioma? (original) (raw)

Related papers